Preview Mode Links will not work in preview mode

May 28, 2024

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics:

  • Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction  treatment (0:00)
  • Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22)
  • Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04)
  • Ongoing research with novel agents and strategies for Ph-positive ALL (24:47)

CME information and select publications